Shanghai Henlius Biotech (SEHK:2696) Advances Cancer Trials, Is It A Bargain?

Shanghai Henlius Biotech (SEHK:2696) is back in focus after Chinese regulators cleared phase 1 trials for its HLX37 combination therapies, while a separate study for bispecific ADC HLX48 has already started dosing patients.

See our latest analysis for Shanghai Henlius Biotech.

The latest HLX37 and HLX48 updates come after a mixed stretch for Shanghai Henlius Biotech, with the share price up 9.77% over 30 days but down 24.54% over 90 days, while the 1 year and 3 year total shareholder returns of 20.27% and very large levels respectively point to strong longer term momentum building behind the story.

If these oncology developments have caught your attention, it could be a good time to see what else is emerging in this space by screening for 130 healthcare AI stocks

Shanghai Henlius Biotech now trades at a sizeable discount to both analyst targets and one assessment of intrinsic value after a choppy share price path. Is the market sensibly cautious about the pipeline risks, or is it mispricing the upside potential?

Preferred P/E of 35.7x: Is it justified?

Shanghai Henlius Biotech currently trades on a P/E of 35.7x, which sits alongside a last close of HK$62.90 and implies the stock is pricing in solid earnings power relative to current profits.

The P/E ratio tells you how much investors are paying today for each unit of earnings, and for a profitable biotech like Shanghai Henlius Biotech it often reflects expectations around the commercial portfolio and late stage pipeline rather than just the latest set of results.

Here, the picture is mixed. The company is described as expensive on a P/E basis compared to similar Hong Kong companies at 33.4x and the broader Asian biotech industry at 30.8x. It also appears expensive versus an estimated fair P/E of 17x that one model suggests the market could move toward over time.

Explore the SWS fair ratio for Shanghai Henlius Biotech

Result: Price-to-earnings of 35.7x (OVERVALUED)

However, Shanghai Henlius Biotech still faces key risks, including potential setbacks in its trial pipeline and pressure on pricing as competition in biologic medicines intensifies.

Find out about the key risks to this Shanghai Henlius Biotech narrative.

Another view on Shanghai Henlius Biotech’s value

While the 35.7x P/E makes Shanghai Henlius Biotech look expensive compared with peers and a 17x fair ratio, the SWS DCF model points the other way. At HK$62.90 versus an estimated HK$189.45 future cash flow value, the stock screens as heavily undervalued. This raises the question of which signal should carry more weight for you.

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Shanghai Henlius Biotech for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 211 high quality undervalued stocks. If you save a screener we even alert you when new companies match – so you never miss a potential opportunity.

Next Steps

With Shanghai Henlius Biotech showing both flagged risks and meaningful potential rewards, it makes sense to check the facts yourself and move quickly to form an informed view by weighing its 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Shanghai Henlius Biotech?

If Shanghai Henlius Biotech has sharpened your interest, do not stop here. Broadening your watchlist now can help you spot opportunities others overlook.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com